Innovating Works

PAPWORTH HOSPITAL NHS FOUNDATION TRUST

Desconocido
RITA-MI 2: Rituximab in patients with acute myocardial infarction a phase 2 placebo controlled randomised clin... PAPWORTH HOSPITAL NHS FOUNDATION TRUST participó en un H2020 H2020-SC1-BHC-2018-2020 RITA-MI 2 will assess the impact of a novel therapeutic strategy targeting patients’ immune response on the recovery of heart function after...
2021-01-18 - 2026-05-31 | Financiado
Track and Know: Big Data for Mobility Tracking Knowledge Extraction in Urban Areas PAPWORTH HOSPITAL NHS FOUNDATION TRUST participó en un H2020 H2020-ICT-2016-2017 Track&Know will research, develop and exploit a new software framework that aims at increasing the efficiency of Big Data applications in th...
2017-11-21 - 2020-12-31 | Financiado
RITA-MI: Rituximab in Acute Myocardial Infarction PAPWORTH HOSPITAL NHS FOUNDATION TRUST participó en un H2020 ERC-2015-PoC Cardiovascular diseases (CVD) represent a major cause of morbidity and mortality. The best current therapy reduces CV risk by only 25-30% an...
2016-02-21 - 2018-08-31 | Financiado
IABC PROGRAMME: iABC Programme PAPWORTH HOSPITAL NHS FOUNDATION TRUST participó en un FP6 Cystic Fibrosis (CF) is a common fatal inherited disease with a frequency of 1 in 2500 live births, affecting approximately 36,000 (0.737/10...
2015-08-01 - 2021-12-31 | Financiado
CFMATTERS: Cystic Fibrosis Microbiome determined Antibiotic Therapy Trial in Exacerbations Results Stratified. PAPWORTH HOSPITAL NHS FOUNDATION TRUST participó en un FP7 Antimicrobial resistance is arguably the most significant challenge facing the EU health care system. The unnecessary use of antibiotics is...
Financiado
IABC PROGRAMME: iABC Programme PAPWORTH HOSPITAL NHS FOUNDATION TRUST participó en un FP7 Cystic Fibrosis (CF) is a common fatal inherited disease with a frequency of 1 in 2500 live births, affecting approximately 36,000 (0.737/10...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.